Prevalence of Flare and Influence of Demographic and Serologic Factors on Flare Risk in Systemic Lupus Erythematosus: A Prospective Study

REFERENCES

1. 1.↵
   1. Liang MH,
   2. Socher SA,
   3. Larson MG,
   4. Schur PH

   . Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107–18.

   OpenUrlPubMed
2. 2.↵
   1. Gladman DD,
   2. Goldsmith CH,
   3. Urowitz MB,
   4. Bacon P,
   5. Bombardier C,
   6. Isenberg D,
   7. et al.

   Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 1992;19:608–11.

   OpenUrlPubMed
3. 3.↵
   1. Ward MM,
   2. Marx AS,
   3. Barry NN

   . Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000;27:664–70.

   OpenUrlPubMed
4. 4.↵
   1. Bae SC,
   2. Koh HK,
   3. Chang DK,
   4. Kim MH,
   5. Park JK,
   6. Kim SY

   . Reliability and validity of Systemic Lupus Activity Measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001;10:405–9.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Petri M,
   2. Hellmann D,
   3. Hochberg M

   . Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992;19:53–9.

   OpenUrlPubMed
6. 6.↵
   1. Gladman DD,
   2. Goldsmith CH,
   3. Urowitz MB,
   4. Bacon P,
   5. Bombardier C,
   6. Isenberg D,
   7. et al.

   Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994;21:1468–71.

   OpenUrlPubMed
7. 7.↵
   1. Hawker G,
   2. Gabriel S,
   3. Bombardier C,
   4. Goldsmith C,
   5. Caron D,
   6. Gladman D

   . A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol 1993;20:657–60.

   OpenUrlPubMed
8. 8.↵
   1. Ruiz-Irastorza G,
   2. Khamashta MA,
   3. Gordon C,
   4. Lockshin MD,
   5. Johns KR,
   6. Sammaritano L,
   7. et al.

   Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale. Arthritis Rheum 2004;51:78–82.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Bencivelli W,
   2. Vitali C,
   3. Isenberg DA,
   4. Smolen JS,
   5. Snaith ML,
   6. Sciuto M,
   7. et al.

   Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:549–54.

   OpenUrlPubMed
10. 10.↵
    1. Mosca M,
    2. Bencivelli W,
    3. Vitali C,
    4. Carrai P,
    5. Neri R,
    6. Bombardieri S

    . The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 200;9:445–50.
11. 11.↵
    1. Bombardieri S,
    2. Vitali C,
    3. Caponi L,
    4. Manca L,
    5. Bencivelli W

    . Activity criteria in systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:S45–8.

    OpenUrlPubMed
12. 12.↵
    1. Isenberg DA,
    2. Rahman A,
    3. Allen E,
    4. Farewell V,
    5. Akil M,
    6. Bruce IN,
    7. et al.

    BILAG 2004 — Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology 2009;48:691–5. Epub 2009 Apr 24.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Symmons DP,
    2. Coppock JS,
    3. Bacon PA,
    4. Bresnihan B,
    5. Isenberg DA,
    6. Maddison P,
    7. et al.

    Development and assessment of a computerised index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 1988;69:927–37.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Hay EM,
    2. Bacon PA,
    3. Gordon C,
    4. Isenberg DA,
    5. Maddison P,
    6. Snaith ML,
    7. et al.

    The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447–58.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Stoll T,
    2. Stucki G,
    3. Malik J,
    4. Pyke S,
    5. Isenberg DA

    . Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996;55:756–60.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Ward MM,
    2. Marx AS,
    3. Barry NN

    . Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000;27:664–70.

    OpenUrlPubMed
17. 17.↵
    1. Isenberg DA,
    2. Gordon C

    . From BILAG to BLIPS — disease activity assessment in lupus past, present and future. Lupus 2000;9:651–4.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Ehrenstein MR,
    2. Conroy SE,
    3. Heath J,
    4. Latchman DS,
    5. Isenberg DA

    . The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view. Br J Rheumatol 1995;34:257–60.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Gordon C,
    2. Sutcliffe N,
    3. Skan J,
    4. Isenberg DA

    . Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003;42:1372–9.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Yee CS,
    2. Farewell V,
    3. Isenberg DA,
    4. Prabu A,
    5. Sokoll K,
    6. Teh LS,
    7. et al.

    Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006;54:3300–5.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Danowski A,
    2. Magder L,
    3. Petri M

    . Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. J Rheumatol 2006;33:57–60.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Kaufman LD,
    2. Gomez-Reino JJ,
    3. Heinicke MH,
    4. Gorevic PD

    . Male lupus: retrospective analysis of the clinical and laboratory features of 52 patients, with a review of the literature. Semin Arthritis Rheum 1989;18:189–97.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Petri M,
    2. Perez-Gutthann S,
    3. Longenecker JC,
    4. Hochberg MC

    . Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991;91:345–53.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Ho A,
    2. Magder L,
    3. Barr S,
    4. Petri M

    . Decreases in anti-double stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2342–9.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Ho A,
    2. Magder LS,
    3. Barr SG,
    4. Petri MA

    . A decrease in complement is associated with increased renal and hematologic flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2350–7.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Tseng CE,
    2. Buyon JP,
    3. Kim M,
    4. Belmont HM,
    5. Mackay M,
    6. Diamond B,
    7. et al.

    The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:3623–32.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Swaak AJG,
    2. Gorenwold J,
    3. Bronsveld W

    . Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986;45:359–66.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Ter Borg EJ,
    2. Horst G,
    3. Hummel EJ,
    4. Limburg PC,
    5. Kallenberg CGM

    . Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum 1990;33:634–43.

    OpenUrlPubMed
29. 29.↵
    1. Alarcon-Segovia D,
    2. Tumlin JA,
    3. Furie RA,
    4. McKay JD,
    5. Cardiel MH,
    6. Strand V,
    7. et al.

    LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442–54.

    OpenUrlCrossRefPubMed